34 results about "Delayed hypersensitivity" patented technology

Procedure for obtaining Olea Europea extracts from Olea Europea leaves dried at less than 35° C. with alkanols at a low temperature and extract purification New pharmacological applications of Olea Europea extracts as an agent reinforcing cellular immunity and delayed hypersensitivity in healthy humans, activating and proliferating T-lymphocytes, Natural Killer cells, monocytes and granulocytes, and pro-inflammatory cytokins.

A compound of formula (I) wherein R<1> and R<2> are as defined in the description, R<2> being an aromatic group, useful in the treatment and condition selected from the group consisting of the group meningitis and salpingitis, septic shock, disseminated intravascular coagulation, and / or adult respiratory distress syndrome, acute or chronic inflammation, arthritis, cholangitis, colitis, encephalitis, endocarditis, glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury, vasculitis, acute and delayed hypersensitivity, graft rejection, and graft-versus-host disease, auto-immune diseases including Type 1 diabetes mellitus and multiple sclerosis, periodonate diseases, interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis, keloid formation tumors which produce IL-1 as an autocrine growth factor, cachexia, Alzeimer's disease, percussion injury, depression, atherosclerosis, osteoporosis in a mammal, including a human.

The invention discloses external traditional Chinese medicine composition with effects of relieving allergy and resisting irritation. The external traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 1-20 parts of campsis grandiflora, 1-10 parts of muskmelon root, 1-10 parts of root of straight ladybell, 1-15 parts of cactuses, 1-10 parts of radix sophorae flavescentis, 1-10 parts of radix ophiopogonis and 1-10 parts of hydrangea aspera don. Experiments prove that the composition has an antagonistic effect on irritation of surfactants and preservatives in cosmetics, has effective effects of inhibiting allergy and relieving itching, and has effects of inhibiting type I hypersensitivity (immediate hypersensitivity) by reducing the content of IL-6 (interleukin-6) and inhibiting type IV hypersensitivity (delayed hypersensitivity) by reducing the content of IL-8. The composition further has effects of whitening and moisturizing skin and achieves the effect of a skin barrier. The raw materials are easily available, a preparation method is simple, convenient, environment-friendly and safe, and the composition is easily accepted by people suffering from allergies, thereby having very good application and market prospects.

The invention relates to a cyclic peptide which is provided with a residue fragment of -Ile-Sta-Pro- and is used as immunosuppressive agents, and the synthesis process of the cyclic peptide (Ile-Ile-Sta-Pro-Tyr-Val-Pro-Leu) consists of 1) removing amino-protecting groups, 2) transpeptidase reaction, 3) the cutting of peptide chain, 4) cyclization of peptide chain. The cyclic peptide compounds which are provided with the residue fragment of -Ile-Sta-Pro- and used as immunosuppressive agents and have a high yield and a high purity can be obtained, and the immunosuppressive activity of the cyclic peptide compounds is higher. Through the experiments of the retarding effect of A1HS1 towards the delayed hypersensitivity of mice, the influence of phagocytic function of macrophages, and the retarding effect of the proliferation of lymphocytes, the A1HS1 shows a stronger immunosuppressive effect than HS-1, which reaches or surpasses the immunosuppressive of the positive contrast (cyclosporine).

A new immunosuppressive agent as glycyrol has significant immunosuppressive activity, thus is useful as an immunosuppressive agent to treat relative diseases, wherein the glycyrol is a coumestrol compound extracted from glycyrrhiza, which is a small molecular compound with novel chemical structure. Tests prove that the glycyrol can inhibit the increment of T lymphocyte induced by canavaline A and inhibit one-way mixed lymphocyte reaction (MLR), release the inflammatory symptom of delayed hypersensitivity and inhibit the homologous allogenic organ transplantation rejection. The glycyrol is a high-effective low-toxicity immunosuppressive agent, with small molecular weight and simple structure, which is easy to be modified and to prepare different drug agents, therefore, the compound is a new generation immunosuppressive agent.

The present invention provides a pharmaceutical composition by a novel action mechanism without serious side effects for delayed hypersensitivity and a screening method of the same. The invention also provides a novel assay method of inhibitors / suppressive agents of PAR-2. The invention relates to a pharmaceutical composition for delayed hypersensitivity containing one or two or more active ingredients selected from the group consisting of inhibitors of PAR-2 and suppressive agents of PAR-2 gene expression and a pharmaceutically acceptable carrier, and to a method for screening active ingredients for pharmaceutical composition for delayed hypersensitivity by contacting a subject substance with cells expressing PAR-2 and by determining expression or activity of PAR-2. The invention also relates to a method for detecting or quantifying actions of the subject substance for PAR-2 using cells expressing PAR-2 in a culture containing inositol.

The invention provides a preparation method for a chlorella immunologic competent peptide. The preparation method is characterized by following steps: adopting a high pressure homogenization method and cellulase / pectinase enzymolysis for extracting chlorella protein, adopting specific proteolysis liquor for enzymolysis, and then separating with an ultrafiltration film, thereby acquiring chlorellaenzymolysis peptides with different molecular weights. According to the invention, compared with other protease enzymatic hydrolysate and polypeptide products with other molecular weight after adopting the same specific proteolysis liquor for enzymolysis, the chlorella peptide with molecular weight of 0-1kDa after adopting specific proteolysis liquor for enzymolysis has better in vitro macrophagemultiplication and phagocytic ability and better capacity for boosting mice delayed hypersensitivity and mice in vivo lymphocyte multiplication and transformation. According to the invention, the preparation for chlorella bioactive peptide with better function of boosting immunity depends on the specific proteolysis liquor, and the development and utilization of immunity-boosting functional healthfood and medicine products are benefited.

The invention provides application of lariciresinol to preparing a medicament for resisting an autoimmune disease and a graft rejection disease. An experiment discovers that: the lariciresinol can inhibit human dendritic cell proliferation in vitro and inhibit the capability of human dendritic cells of promoting allogeneic T cell proliferation reaction and enhancing the secretion of interleukin 10. Meanwhile, in an experimental autoimmune myelomeningitis model, the lariciresinol is applied in vivo, so that an average clinical score of mice can be reduced and the spinal infiltration of mononuclear cells is inhibited. In a heart transplant experiment, the lariciresinol is applied in vivo, so that the survival time of a transplanted heart is prolonged. In a delayed hypersensitivity model, the lariciresinol is applied in vivo, so that the auricle swelling degree of the mice can be reduced. In-vivo and in-vitro results both show that: the lariciresinol has the certain effect of resisting the autoimmune disease and graft rejection disease. The medicament is a preparation which consists of the lariciresinol serving as an active ingredient and a medical carrier, and comprises an oral preparation, an injection, a suppository, an external preparation and the like.

The invention relates to a cyclic peptide which is provided with a residue fragment of -Val-Sta-Leu- and is used as immunosuppressive agents, and the synthesis process of the cyclic peptide (Ile-Ile-Pro-Pro-Tyr-Val-Sta-Leu) consists of 1) removing amino-protecting groups, 2) transpeptidase reaction, 3) the cutting of a peptide chain, 4) cyclization of the peptide chain. The cyclic peptide compounds which are provided with the residue fragment of Val-Sta-Leu- and used as immunosuppressive agents and have a high yield and a high purity can be obtained, and the immunosuppressive activity of the cyclic peptide compounds is higher. Through the experiments of the retarding effect of A3HS1 towards the delayed hypersensitivity of mice, the influence of phagocytic function of macrophages, and the retarding effect of the proliferation of lymphocytes, the A3HS1 shows a stronger immunosuppressive effect than HS-1, which reaches or surpasses the immunosuppressive of the positive contrast (cyclosporine).

The invention belongs to the technical field of plant extraction and especially relates to a grapefruit extracting method. The grapefruit extracting method disclosed by the invention comprises the following steps: a) smashing grapefruit whole fruit to obtain homogenate; b) performing micro-jet extraction on the homogenate to obtain extractive. The extracting method has advantages of high extracting efficiency, small damage to an effective ingredient of general flavones in the grapefruit, ability in keeping functional components of the grapefruit, energy conservation and environmental friendliness. A mass fraction of the general flavones of the grapefruit extractive obtained by the extracting method can reach 50%, a content of the effective ingredient of the general flavones is high, and grapefruit function exerting is facilitated; experiments show that the grapefruit extractive has a strong anti-allergy function and especially shows obvious anti-inflammation and antibacterial functionsin the aspects of resisting delayed hypersensitivity and reducing capillary permeability. The invention further provides application of the grapefruit extractive obtained by the extracting method inpreparing anti-allergy products, anti-inflammation products and / or antibacterial products.

The invention relates to cyclic peptide used as immunosuppressant and carried with -Pro-Sta-Tyr- residue fragment as well as ring (Ile-Ile-Pro-Sta-Tyr-Val-Pro-Leu). The synthesis process of the invention is as follows: (1) amino protecting group is removed; (2) synthesized peptide is completed; (3) peptide chain cutting is carried out; (4) peptide chain cyclization is completed. Therefore, a cyclic peptide compound, which has high yield, high purity and -Pro-Sta-Tyr- residue fragment and can be used as immunosuppressant, can be obtained; moreover, the compound has higher immunosuppression activity. The experiments on the inhibition of A2HS1 on mouse delayed hypersensitivity, the influence on the phagocytic capability of macrophage and the inhibition on lymphopoiesis show that the A2HS1 represents stronger natural immunosuppression than HS-1 and reaches or exceeds positive contrast (cyclosporin) immunosuppression.

An application of fumigaclavine C in treating Crohn's disease, ulcerative colitis, and T cell-related autoimmune diseases, such as delayed hypersensitivity, multiple sclerosis, insulin-dependent diabetes, etc, is disclosed.

The invention discloses a health-care food for enhancing immunity and application thereof. The health-care food is prepared from, by weight, 1400-1650 parts of honeysuckle flowers, 1400-1650 parts ofporia cocos, 900-1100 parts of Chinese mosla Herb, 2400-2600 parts of hawthorns and 2400-2600 parts of Chinese dates. According to the recuperating theory of traditional chinese dietary therapy and aclinical experience formula, the selected raw materials are recorded in the Chinese pharmacopoeia 2010. An experiment proves that the acute toxicity of the health-care food belongs to the non-toxic level, delayed hypersensitivity of rats and antibody generating cell proliferation of the rats are promoted, and the health-care food has no obvious influence on the weight, organ / weight ratio and NK cell viability of the rats. Therefore, the health-care food has the wide application prospect on the aspect of immunity enhancing.

The invention discloses a medical traditional Chinese medicine coupling agent and a preparation method thereof. The medical traditional Chinese medicine coupling agent is prepared from the following raw materials: guar gum, Carbomer, menthol, lysine, potassium triethylenediamine tetraacetate, anisic aldehyde, theaspirane, baicalin, compound traditional Chinese medicine extract, triisopropanolamine, phosphoric acid, glycerinum and distilled water. The medical coupling agent provided by the invention has good sterilizing effect both for bacteria and pathogenic fungi, and is wide in antibiosis and fast in sterilization. In addition, an ultrasonic attenuation value of the medical coupling agent is small, no irritation phenomenon is present, a probe is not corroded and damaged, various performance indexes are hardly changed when the medical traditional Chinese medicine coupling agent is stored for a year at room temperature, the stability is excellent, and the sensitization and various performance indexes of a delayed hypersensitivity test specimen are good.

The invention discloses a traditional Chinese medicinal health food having fatigue preventing and immunity enhancing effects. The health food is prepared from, by weight, 50-150 parts of hairy antler,150-400 parts of epimedium herb, 250-450 parts of Fructus Tribuli, 150-400 parts of ginseng, 150-400 parts of Radix Puerariae, 150-400 parts of mulberry and 150-400 parts of Polygonatum sibiricum. The invention also discloses a preparation method of the health food. The health food can prolong the weight-loading swimming of mice, increase the number of antibody-producing cells in the mice, increase the half hemolysis value of the serum of the mice and improve the delayed hypersensitivity of the mice, so the health food has the fatigue preventing and immunity enhancing functions.

It was revealed that a cell fraction of Lactobacillus gasseri, which has been eaten, and the safety of long-term ingestion of which has been ensured, suppresses a delayed hypersensitive reaction. Therefore, the invention provides an agent for alleviating delayed hypersensitivity containing a cell fraction of Lactobacillus gasseri. Further, the invention provides a food composition for alleviating delayed hypersensitivity containing the cell fraction of Lactobacillus gasseri. In the invention, it was revealed that an RNA fraction of the cell fraction has a particularly high effect of suppressing a delayed hypersensitive reaction.

The invention provides an application of Incarvillea delavay alkali in preparing a drug for resisting autoimmune diseases and graft rejection diseases. Experiments show that the Incarvillea delavay alkali can inhibit human dendritic cell proliferation in vitro, prevent the human dendritic cells from accelerating the proliferation reaction of allogeneic T cells, and strengthen the capability of the human dendritic cell on secreting interleukin. Meanwhile, in the model of the experimental autoimmune disease cerebrospinal meningitis, the Incarvillea delavay alkali is applied in vivo so as to lower average clinical scores of mice and inhibit the spinal cord infiltration degree of mononuclear cells. In a heart transplantation experiment, the Incarvillea delavay alkali is applied in vivo to prolong the survival time of a transplanted heart. In a delayed hypersensitivity reaction model, the Incarvillea delavay alkali is applied in vivo to lower the auricle swelling degree of the mice. In-vivo and in-vitro results show that the Incarvillea delavay alkali has certain action on resisting autoimmune diseases and graft rejection diseases. The drug provided by the invention is a preparation composed of the Incarvillea delavay alkali which serves as an active ingredient, and a medicinal carrier. The drug can be in an oral agent form, an injection form, a suppository form or an external dosage form and the like.

The invention discloses a traditional Chinese medicinal composition for treating eczema and application thereof. The formula consists of Chinese thorowax root, white paeony root, immature bitter orange and licorice root in the weight ratio of (0.8-1.2):(0.8-1.2):(0.8-1.2):(0.8-1.2). The traditional Chinese medicinal composition is simple in composition; the effect of inhibiting delayed hypersensitivity besides the conventional effects of warming and smoothing meridians of the traditional Chinese medicinal composition in the formula are found for the first time, and the traditional Chinese medicinal composition has a good treatment effect on the eczema.

The invention discloses a product based on a nontuberculous-mycobacterium purified protein derivative and a recombinant mycobacterium tuberculosis fusion protein, application and a use method and belongs to the technical field of biological proteins. Tuberculosis and a NTM disease can be rapidly and accurately identified through combined use of the nontuberculous mycobacterium purified protein derivative and the recombinant mycobacterium tuberculosis fusion protein (EEC), and when delayed hypersensitivity reactions of the nontuberculous mycobacterium purified protein derivative and the recombinant mycobacterium tuberculosis fusion protein are all positive, the tuberculosis is determined; and when the delayed hypersensitivity reaction of the nontuberculous-mycobacterium purified protein derivative is positive and the delayed hypersensitivity reaction of the recombinant mycobacterium tuberculosis fusion protein is negative, the NTM disease is determined. The invention provides the product based on the nontuberculous-mycobacterium purified protein derivative and the recombinant mycobacterium tuberculosis fusion protein and the application of the product, so that the tuberculosis and the NTM disease are quickly and accurately identified, and a reliable basis is provided for the aspects of early diagnosis, treatment and the like of patients.

The invention relates to a cyclic peptide which is provided with a residue fragment of -Val-Sta-Leu- and is used as immunosuppressive agents, and the synthesis process of the cyclic peptide (Ile-Ile-Pro-Pro-Tyr-Val-Sta-Leu) consists of 1) removing amino-protecting groups, 2) transpeptidase reaction, 3) the cutting of a peptide chain, 4) cyclization of the peptide chain. The cyclic peptide compounds which are provided with the residue fragment of Val-Sta-Leu- and used as immunosuppressive agents and have a high yield and a high purity can be obtained, and the immunosuppressive activity of the cyclic peptide compounds is higher. Through the experiments of the retarding effect of A3HS1 towards the delayed hypersensitivity of mice, the influence of phagocytic function of macrophages, and the retarding effect of the proliferation of lymphocytes, the A3HS1 shows a stronger immunosuppressive effect than HS-1, which reaches or surpasses the immunosuppressive of the positive contrast (cyclosporine).

The invention discloses an application of BMS470539 to preparation of a medicine for treating Alzheimer's disease. The medicine internally contains BMS470539, a raisin tree seed extract, a spina date seed extract, a lemon extract, industrial hemp flowers and bilobalide, and the BMS470539 is an effective and selective melanocortin-1 (MC1) receptor agonist. Research finds that the compound has a certain effect in human melanoma cells, a mouse model in which LPS (lipopolysaccharide) induces cell factor accumulation, a mouse pneumonia model, a delayed hypersensitivity reaction model and other disease models in experiments. Laboratory research finds that the BMS470539 can significantly improve pathological symptoms and improve the memory level in an Alzheimer's disease animal model, the application effect of the BMS470539 in Alzheimer's diseases is obtained through a large number of experiments, particularly, the BMS470539 can significantly improve the memory ability of Alzheimer's disease mice in conditional fear experiments, the stiffness level is significantly increased, and the application potential in treatment of the Alzheimer's disease is shown.

An alkaline plant salt boosting immunity is provided. The alkaline plant salt comprises a suaeda salsa plant salt, a undaria pinnatifida extract product, dry banana powder, a cordyceps militaris sporocarp extract product, a common yam rhizome extract product, a cassia seed extract product, amorphophallus konjak powder, tea polyphenols and fucoidin. A preparing method of the alkaline plant salt is also provided. The alkaline plant salt is capable of increasing weights of immune organs, boosting body fluid immunity, increasing the hemolysin content, boosting nonspecific immunity of mice, significantly increasing the phagocytic index and phagocytic activity of phagocytes of mice, improving delayed hypersensitivity of mice and increasing the quantity of antibody producing cells.

The invention discloses a product based on an intracellular mycobacterium pure protein derivative and a recombinant mycobacterium tuberculosis fusion protein and application of the product, and belongs to the technical field of biological protein. According to the present invention, the tuberculosis and the NTM disease can be rapidly identified (within 24 h) through the combined use of the intracellular mycobacterium pure protein derivative and the recombinant mycobacterium tuberculosis fusion protein (EEC), and the tuberculosis is determined when the delayed hypersensitivity reactions of the intracellular mycobacterium pure protein derivative and the recombinant mycobacterium tuberculosis fusion protein (EEC) are completely positive; and when the delayed hypersensitivity reaction of the intracellular mycobacterium pure protein derivative is positive and the delayed hypersensitivity reaction of the recombinant mycobacterium tuberculosis fusion protein (EEC) is negative, the disease is NTM disease. The invention aims to provide a product based on an intracellular mycobacterium pure protein derivative and a recombinant mycobacterium tuberculosis fusion protein and application of the product, so that tuberculosis and NTM diseases are quickly identified, and a reliable basis is provided for an accurate treatment scheme of a patient.

The invention relates to the application of ginseng alkynol for preparing medicine treating delayed hypersensitivity diseases, in particular to the application of the ginseng alkynol for preparing the medicine treating contact dermatitis, the application of the ginseng alkynol for preparing the medicine treating hypersensitivity pneumonia, the application of the ginseng alkynol for preparing the medicine treating homograft rejection, and the application of the ginseng alkynol for preparing the medicine treating granulomatosis caused by pathogene in cells. The ginseng alkynol is used as main active ingredient used for treating the delayed hypersensitivity diseases, can obviously inhibit the diseases mediated by delayed hypersensitivity, has no obvious inhibition to immune organs and other cells, and is hopeful to be higher effective and lower toxic medicine used for treating the delayed hypersensitivity diseases.

The invention discloses a traditional Chinese medicinal spray for treating plaster allergy and a preparation method thereof. The spray is composed of the following raw materials in percentages by weight: 50%-70% of fresh hawthorn, 20%-30% of green plum and 10%-20% of pericarpium citri reticulatae; and auxiliary materials comprise the following components in percentages by volume based on the totalvolume of a prepared medicinal solution: 5%-10% of glycerol and 0.5%-1.5% of water-soluble azone. The preparation method comprises the following steps: weighing the fresh hawthorn, the green plum andthe pericarpium citri reticulatae which are treated, carrying out soaking in an ethanol solution with a concentration of 30%-40% for a plurality of hours, taking a leaching solution, and carrying outconcentration under reduced pressure until alcohol smell is removed; and filling a concentrate into a macroporous resin column, carrying out elution with water to remove impurities, collecting eluateobtained through elution with 10% ethanol, concentrating the eluate to a certain volume, carrying out filtering, then adding the glycerol and the water-soluble azone, and carrying out uniform mixingunder stirring. Pharmacodynamic test results prove that the medicine provided by the invention has significant effect of resisting inflammatory and delayed hypersensitivity, and has an exact treatmenteffect on the plaster allergy.

The invention relates to the application of ginseng alkynol for preparing medicine treating delayed hypersensitivity diseases, in particular to the application of the ginseng alkynol for preparing the medicine treating contact dermatitis, the application of the ginseng alkynol for preparing the medicine treating hypersensitivity pneumonia, the application of the ginseng alkynol for preparing the medicine treating homograft rejection, and the application of the ginseng alkynol for preparing the medicine treating granulomatosis caused by pathogene in cells. The ginseng alkynol is used as main active ingredient used for treating the delayed hypersensitivity diseases, can obviously inhibit the diseases mediated by delayed hypersensitivity, has no obvious inhibition to immune organs and other cells, and is hopeful to be higher effective and lower toxic medicine used for treating the delayed hypersensitivity diseases.